News from the MCRC
Impact Case Study
PROCAS 2
Professor David French discusses assessing the benefits and harms of risk stratified screening as part of the NHS Breast Screening Programme.
Impact Case Study
PROCAS and BC-PREDICT
We speak to Professor Gareth Evans about how the findings from PROCAS 1 led to the inception of PROCAS 2, which assesses the feasibility of implementing a personalised risk score into a woman’s first screening appointment and the associated impact on NHS staff, patients and other related organisations.
Partner News
10/05/2022
Indoor tanning ban would reduce melanoma deaths, show researchers
Director's Update
05/05/2022
MCRC Director’s Update – April 2022
Director's Update
25/03/2022
MCRC Director’s Update – March 2022
Visiting leadership in Kenya, five more years of funding for the Cancer Research UK Manchester Centre, and a visit to Westminster to launch On Cancer close an eventful March for the MCRC.
Director's Update
25/03/2022
On Cancer Westminster Launch
MCRC Blog
24/03/2022
The ALETHEIA framework in radiation oncology
Dr Marianne Aznar explains the ALETHEIA Framework, an AI toolkit developed by Rolls-Royce, and how it is being applied to radiation oncology
MCRC Blog
16/03/2022
MCRC-DCS Alumni Showcase
Partner News
14/03/2022
New era for Kenyan healthcare begins
Representatives of the MCRC partnership were in Kenya for the 14th March to mark the development of a Comprehensive Cancer Care Services network.
Director's Update
04/03/2022
MCRC Director’s Update – February 2022
Researcher Stories
02/03/2022
Thomas Kedward
We speak to Thomas Kedward about his PhD and the use of proteogenomics to connect somatic mutations to signalling in
breast cancer patient-derived organoids.
Director's Update
04/02/2022
Introducing On Cancer
Researcher Stories
17/01/2022
Hadiyat Ogunlayi
We speak to Hadiyat Ogunlayi about breast cancer and her MB-PhD investigating the relationship between a stromal wound healing phenotype and breast density as a mechanism for breast cancer development.
Research Spotlight
05/01/2022
Cancer researchers across the UK join forces to find drugs for rare cancers
DETERMINE is the first UK national precision medicine trial in rare cancers, testing a range of therapies specifically targeting key genetic changes in cancer cells.
